1,1'-dimethyl-spiro[indoline-3,4'-piperidine]

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,1'-dimethyl-spiro[indoline-3,4'-piperidine]
• 英文别名: 1,1'-Dimethyl-spiro[indolin-3,4'-piperidin]；1,1'-dimethylspiro[2,3-dihydro-1H-indole-3,4'-piperidine]；1,1'-dimethylspiro[2H-indole-3,4'-piperidine]
• 化学式: C₁₄H₂₀N₂
• 分子量: 216.326
• InChiKey: WPHCNVGJJXMICX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1'-dimethyl-spiro[indoline-3,4'-piperidine] 在 1-氯乙基氯甲酸酯 、 甲醇 、 sodium hydroxide 作用下， 以 1,2-二氯乙烷 、 水 、 乙酸乙酯 为溶剂， 反应 18.0h， 生成 1-methylspiro[indolin-3,4'-piperidine]
  参考文献：
  名称：

  EP1726590

  摘要：

  公开号：
• 作为产物：
  描述：

  1,1'-dimethyl-1H-spiro[indole-3,4'-piperidin]-2-one 在 四氢呋喃 、 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1,1'-dimethyl-spiro[indoline-3,4'-piperidine]
  参考文献：
  名称：

  关于类毒扁豆碱体的合成

  摘要：

  为了研究化学组成与毒扁豆碱样作用之间的关系，建立了1-甲基-3-螺-（N-甲基-哌啶-4）-5-N-甲基氨基甲酰二氢吲哚。在6-位直至乙氧基-二氢吲哚阶段进行相应的氨基甲酸酯的合成，在7-位直至羟氧吲哚阶段的类似物的合成。

  DOI：

  10.1002/hlca.19520350218

文献信息

• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。
• CYCLIC AMIDE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20130203739A1

  公开（公告）日：2013-08-08

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR 7 —; J 1 is —CR 11a R 11b — or —NR 11c —; J 2 is —CR 12a R 12b — or —NR 12c —; and R 1 to R 12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  为提供一种具有GPR40激活剂作用的新化合物、该化合物的盐、盐或化合物的溶剂合物，尤其是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药剂，解决问题的方法是使用Formula (1)的化合物：(其中n为0至2；p为0至4；h为0至3；j为0至3；k为0至2；环B为芳香族或杂环芳基；X为O、S或-NR7-；J1为-CR11aR11b-或-NR11c-；J2为-CR12aR12b-或-NR12c-；R1到R12为特定基团)，该化合物的盐，或盐或化合物的溶剂合物。
• NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
  申请人：OHKOUCHI Munetaka

  公开号：US20120277150A1

  公开（公告）日：2012-11-01

  [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.

  提供一种包含GPR40激活剂的药剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、该化合物或盐的溶剂化合物等，特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药物。解决问题的方法是使用式(I)的化合物：（其中p为0至4；j为0至2；k为0至1；环A为芳基、杂环基、环烷基、环烯基、螺环基；环B为芳基、杂芳基；X为0或-NR7-；R1至R7和L为特定基团），该化合物的盐或该化合物或盐的溶剂化合物。
• Cycloalkanopyridine derivative
  申请人：Takahashi Hirobumi

  公开号：US20070191419A1

  公开（公告）日：2007-08-16

  Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

  提供的是式[I]的环烷基吡啶衍生物：[其中符号与说明中所述相同]。这些化合物作为一种nociceptin受体拮抗剂，可用作与nociceptin受体相关的疾病的药物，例如作为缓解对麻醉镇痛剂的耐受性的药物；对麻醉镇痛剂的依赖或成瘾的缓解剂；镇痛增强剂；抗肥胖或食欲抑制剂；治疗或预防认知障碍和失忆症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁或治疗情感障碍的药物；治疗或预防尿崩症的药物；治疗或预防多尿症的药物；或治疗低血压的药物。
• NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20130210721A1

  公开（公告）日：2013-08-15

  [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.

  [目的] 提供一种GPR40激活剂，其中包含一种具有GPR40激动剂作用的新化合物作为活性成分，该化合物的盐、化合物或盐的溶剂合物等，特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症或其他疾病的药物。 [解决问题的方法] 公式(I)的化合物： 其中p为0至4；j为0至2；k为0至1；环A为芳基、杂环基、环烷基、环烯基、螺环基；环B为芳基、杂芳基；X为O或-NR7-；R1至R7和L为特定的基团，该化合物的盐或化合物或盐的溶剂合物。